Regulators from the European Medicines Agency are paying close attention to the UK’s fledgling but “incredible” innovative licensing and access pathway (ILAP), which aims to speed up access to medicines with greater alignment between regulatory and health technology assessment (HTA) processes, heard delegates at a regulatory symposium. The EMA also acknowledged that it could “do better” when it comes to engaging with HTA bodies to ensure that its expedited program, the PRIME (priority medicines) scheme, delivers patient access to medicines more quickly.
European Expedited Programs & Harnessing HTA
European regulators are exploring their interactions with health technology appraisal bodies to improve expedited programs that aim to get medicines to patients more quickly.
More from Europe
More from Conferences
• By
Sponsors should review longstanding agency concepts on consumer-friendly language and claims limitations, along with Office of Prescription Drug Promotion research and enforcement, when applying the 2018 CFL guidance to direct-to-consumer advertising, Sidley Austin’s Cope says.
• By
Center for Biologics Evaluation and Research Director Peter Marks expects no fundamental changes in support for FDA initiatives and said the Rare Disease Innovation Hub, which promotes cross-center collaboration, is “consistent with what we're hearing in the current environment.”
• By
Sponsors should consider the DTC ad's audio as the major statement about a prescription drug’s side effects and then choose strategically how to display the accompanying text. TV ads are now employing banners and larger text to satisfy the rule’s “dual modality” requirement.